ストックスクリーナーアプリを入手
6.92
2.26%
-0.16
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Phathom starts Phase 3 trial: Phathom Pharmaceuticals stock faces 2028 results - AD HOC NEWS
Phathom Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:PHAT - TradingView
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD - Investing.com
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Phathom starts phase 3 trial of Voquezna for heartburn relief - Investing.com
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD - GlobeNewswire
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Sep 2026 $PHAT - MarketBeat
Technical Reactions to PHAT Trends in Macro Strategies - Stock Traders Daily
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law - The National Law Review
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals targets gastroenterolog... - Pluang
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - finance.yahoo.com
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom (PHAT) Levels: Ends Up by 0.39% at $8.90 for the Current Session; Chart View: the Supplied Trading Band Runs From $8.46 to $9.35 on the DayNHNL Divergence - dars.gov.et
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup - dars.gov.et
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - theglobeandmail.com
PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Phathom Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | PHAT | US71722W1071 - marketscreener.com
PHAT Holds Near $9.18 as Phathom Pharmaceuticals Consolidates Within Key Trading RangeStop Hunt - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Why (PHAT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Edges Higher at $8.57: Support Holds as Resistance LoomsTriangle Correction - dars.gov.et
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuti - The National Law Review
Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Phathom Pharmaceuticals, Inc. (PHAT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Reach Out - ACCESS Newswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5%Here's Why - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT) - Business Wire
Weekly Recap: Q2 revenue surge and Investigation into NASDAQ:PHAT guidance claim - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out - ACCESS Newswire
925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-08-01 - Seeking Alpha
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):